Hanol IP & Law
Sponsored
Sponsored
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law summarises the eligible drugs, the re-examination period and strategies available for companies
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law explains how the recent Supreme Court en banc ruling changes precedents on infringement by the use of later-registered trademarks
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law describes how patent challenges have become even more important under the revised drug pricing framework in South Korea
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law looks at how the Korean Intellectual Property Office (KIPO) and the Korean courts have judged the registrability and validity of pharmaceutical trademarks according to more specific criteria
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021
-
Sponsored by Hanol IP & LawKorea Seed Industry Act (KSIA) and its Implementing Regulation, effective as of June 19 2020, a person who intends to sell propagating materials of certain types of foreign plant varieties should report this fact to the Ministry for Agriculture Food and Rural Affairs (MAFRA), along with submission of evidence proving that such propagating materials have been "legally obtained" (Article 38 of KSIA, Article 27 of Implementing Regulation thereof). In other words, in order to sell propagating materials of foreign plant varieties in Korea, a seed supplier shall have a duty to prove that he has lawfully acquired the same.